FY2024 EPS Estimates for Immunocore Raised by HC Wainwright

Immunocore Holdings plc (NASDAQ:IMCR) – Analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for shares of Immunocore in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($1.33) per share for the year, up from their previous forecast of ($2.14). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for Immunocore’s Q4 2024 earnings at ($0.78) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($2.41) EPS, FY2026 earnings at ($2.34) EPS, FY2027 earnings at $1.04 EPS and FY2028 earnings at $4.21 EPS.

Several other equities analysts have also commented on IMCR. Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $72.00 to $38.00 in a research report on Monday. Morgan Stanley dropped their price target on Immunocore from $80.00 to $74.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. Barclays dropped their target price on Immunocore from $92.00 to $66.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Finally, Needham & Company LLC decreased their price target on Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat, Immunocore currently has a consensus rating of “Moderate Buy” and an average price target of $69.18.

Immunocore Stock Down 0.1 %

NASDAQ IMCR opened at $34.64 on Monday. The stock has a 50 day moving average price of $32.61 and a 200-day moving average price of $39.09. Immunocore has a one year low of $29.72 and a one year high of $76.98. The company has a debt-to-equity ratio of 1.03, a quick ratio of 5.15 and a current ratio of 3.78. The company has a market capitalization of $1.73 billion, a P/E ratio of -36.46 and a beta of 0.72.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.33) by $0.50. The business had revenue of $80.25 million for the quarter, compared to analysts’ expectations of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.59) EPS.

Institutional Trading of Immunocore

Hedge funds have recently bought and sold shares of the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Immunocore by 86.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 342,000 shares of the company’s stock valued at $22,230,000 after purchasing an additional 158,455 shares during the last quarter. Orion Portfolio Solutions LLC lifted its position in Immunocore by 33.7% during the first quarter. Orion Portfolio Solutions LLC now owns 23,127 shares of the company’s stock valued at $1,503,000 after acquiring an additional 5,826 shares during the last quarter. Nan Fung Group Holdings Ltd purchased a new stake in Immunocore during the first quarter valued at approximately $439,000. Janus Henderson Group PLC boosted its stake in Immunocore by 45.8% in the first quarter. Janus Henderson Group PLC now owns 257,080 shares of the company’s stock valued at $16,711,000 after acquiring an additional 80,748 shares in the last quarter. Finally, Tidal Investments LLC purchased a new position in Immunocore in the first quarter worth $423,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.